Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells

BACKGROUND: The mechanism of action of oral cladribine, recently licensed for relapsing multiple sclerosis, is unknown. OBJECTIVE: To determine whether cladribine depletes memory B cells consistent with our recent hypothesis that effective, disease-modifying treatments act by physical/functional dep...

Descripción completa

Detalles Bibliográficos
Autores principales: Ceronie, Bryan, Jacobs, Benjamin M., Baker, David, Dubuisson, Nicolas, Mao, Zhifeng, Ammoscato, Francesca, Lock, Helen, Longhurst, Hilary J., Giovannoni, Gavin, Schmierer, Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937883/
https://www.ncbi.nlm.nih.gov/pubmed/29550884
http://dx.doi.org/10.1007/s00415-018-8830-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937883/
https://www.ncbi.nlm.nih.gov/pubmed/29550884
http://dx.doi.org/10.1007/s00415-018-8830-y

Ejemplares similares